This study looks at a new treatment for pancreatic cancer, particularly a type called pancreatic ductal adenocarcinoma (PDAC), which is linked to a gene change known as a KRAS mutation. The study examines a treatment that combines a cancer vaccine called ELI-002 7P with chemotherapy drugs (mFOLFIRINOX: 5-Fluorouracil, oxaliplatin, leucovorin, irinotecan) and possibly another drug, Tislelizumab. The goal is to see if this combination is safe and effective.

• This is a pilot study, which means it's a preliminary study to test if the treatment should be studied further.
• Participants need to have a specific type of pancreatic cancer that can potentially be removed by surgery.
• Patients must be 18 or older, not pregnant, and willing to use effective contraception if they can have children.

Key Points:

• Participants must commit to multiple visits and procedures.
• There is careful monitoring for side effects and effectiveness.
• Potential risks include treatment reactions or not being effective for every patient.